BACKGROUND: There is little information about the immune reconstitution syndrome (IRS) in children, especially from resource-poor countries. OBJECTIVE: To determine the incidence and spectrum of IRS in advanced stage human immunodeficiency virus (HIV)-infected children after initiation of highly active antiretroviral therapy (HAART). METHODS: Between May 2002 and April 2004, 153 symptomatic HIV-infected children who had CD4 lymphocyte percentage < or =15% initiated HAART in a national antiretroviral drug access program. All patients were followed for 48 weeks. In this study, IRS was defined as a disease event caused by microorganisms or conditions previously reported to be associated with IRS in patients having immunologic and/or virologic response to HAART. RESULTS: The incidence of IRS was 19% (95% confidence interval, 13.1-26.1). The median time of onset was 4 weeks after start of HAART (range, 2-31). There were 32 episodes of IRS, including 14 caused by mycobacterial organisms, 7 by varicella-zoster virus, 7 by herpes simplex virus, 3 by Cryptococcus neoformans and 1 episode of Guillain-Barré syndrome. Patients who had IRS develop had lower baseline CD4 lymphocyte percentages compared with those who did not (P = 0.02). CONCLUSIONS: IRS is common among HIV-infected children who received HAART in their advanced stage of disease. Educational programs for patients and health care workers on recognizing and treating these conditions should be integrated into antiretroviral treatment access programs.
BACKGROUND: There is little information about the immune reconstitution syndrome (IRS) in children, especially from resource-poor countries. OBJECTIVE: To determine the incidence and spectrum of IRS in advanced stage human immunodeficiency virus (HIV)-infectedchildren after initiation of highly active antiretroviral therapy (HAART). METHODS: Between May 2002 and April 2004, 153 symptomatic HIV-infectedchildren who had CD4 lymphocyte percentage < or =15% initiated HAART in a national antiretroviral drug access program. All patients were followed for 48 weeks. In this study, IRS was defined as a disease event caused by microorganisms or conditions previously reported to be associated with IRS in patients having immunologic and/or virologic response to HAART. RESULTS: The incidence of IRS was 19% (95% confidence interval, 13.1-26.1). The median time of onset was 4 weeks after start of HAART (range, 2-31). There were 32 episodes of IRS, including 14 caused by mycobacterial organisms, 7 by varicella-zoster virus, 7 by herpes simplex virus, 3 by Cryptococcus neoformans and 1 episode of Guillain-Barré syndrome. Patients who had IRS develop had lower baseline CD4 lymphocyte percentages compared with those who did not (P = 0.02). CONCLUSIONS: IRS is common among HIV-infectedchildren who received HAART in their advanced stage of disease. Educational programs for patients and health care workers on recognizing and treating these conditions should be integrated into antiretroviral treatment access programs.
Authors: Samuel A Shelburne; Richard J Hamill; Maria C Rodriguez-Barradas; Stephen B Greenberg; Robert L Atmar; Daniel W Musher; Joseph C Gathe; Fehmida Visnegarwala; Barbara W Trautner Journal: Medicine (Baltimore) Date: 2002-05 Impact factor: 1.889
Authors: M A French; N Lenzo; M John; S A Mallal; E J McKinnon; I R James; P Price; J P Flexman; M L Tay-Kearney Journal: HIV Med Date: 2000-03 Impact factor: 3.180
Authors: Peter J Piliero; Douglas G Fish; Sandra Preston; Donna Cunningham; Tosca Kinchelow; Miklos Salgo; Jiang Qian; George L Drusano Journal: Clin Infect Dis Date: 2003-04-14 Impact factor: 9.079
Authors: N Kumarasamy; Suniti Solomon; Timothy P Flanigan; R Hemalatha; S P Thyagarajan; Kenneth H Mayer Journal: Clin Infect Dis Date: 2002-12-09 Impact factor: 9.079
Authors: Kristopher R Bosse; Eric A Russell; Kudakwashe R Chikwava; Richard M Rutstein; Elizabeth Lowenthal Journal: Pediatr Infect Dis J Date: 2013-09 Impact factor: 2.129
Authors: A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch Journal: HIV Med Date: 2015-02-03 Impact factor: 3.180
Authors: Patricia Price; David M Murdoch; Upasna Agarwal; Sharon R Lewin; Julian H Elliott; Martyn A French Journal: Clin Microbiol Rev Date: 2009-10 Impact factor: 26.132
Authors: Eric D McCollum; Geoffrey A Preidis; Madalitso Maliwichi; Dan Olson; L Madeline McCrary; Peter N Kazembe; Charles van der Horst; Irving Hoffman; Mina C Hosseinipour Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731